Author:
Garon Edward B.,Spira Alexander I.,Goldberg Sarah B.,Chaft Jamie E.,Papadimitrakopoulou Vassiliki,Cascone Tina,Antonia Scott J.,Brahmer Julie R.,Camidge D. Ross,Powderly John D.,Wozniak Antoinette J.,Felip Enriqueta,Wu Song,Ascierto Maria L.,Elgeioushi Nairouz,Awad Mark M.
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference26 articles.
1. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015
2. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial;Sezer;Lancet,2021
3. Atezolizumab for first-line treatment of PD-L1-selected patients with NSCLC;Herbst;N Engl J Med,2020
4. The landscape of immunotherapy resistance in NSCLC;Frisone;Front Oncol,2022
5. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade;Wei;Cell,2017